Matthew Paul Kowalsky

Insider Reports History

Location
Marblehead, MA
Signature
/s/ Matthew Kowalsky
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Matthew Paul Kowalsky:

Company Role Class Num Shares Value Price $ Report Date Ownership
ENANTA PHARMACEUTICALS INC Chief Legal Officer Common Stock 3,591 $51,171 $14.25 12 Feb 2026 Direct
ENANTA PHARMACEUTICALS INC Chief Legal Officer Stock Option (right to buy) 90,000 25 Nov 2025 Direct
Sigilon Therapeutics, Inc. CHIEF OF STAFF AND CLO Common Stock 0 11 Aug 2023 Direct
Sigilon Therapeutics, Inc. CHIEF OF STAFF AND CLO Stock Option (Right to Buy) 0 $0.7500 11 Aug 2023 Direct

Insider Reports Filed by Matthew Paul Kowalsky

Symbol Company Period Transactions Value $ Form Type Role Filing Time
ENTA ENANTA PHARMACEUTICALS INC 12 Feb 2026 3 -$27,104 4 Chief Legal Officer 13 Feb 2026, 16:33
ENTA ENANTA PHARMACEUTICALS INC 25 Nov 2025 1 $0 4 Chief Legal Officer 26 Nov 2025, 17:08
ENTA ENANTA PHARMACEUTICALS INC 27 Nov 2024 1 $0 4 Chief Legal Officer 27 Nov 2024, 17:10
ENTA ENANTA PHARMACEUTICALS INC 29 Apr 2024 1 $0 4 Chief Legal Officer 01 May 2024, 16:27
ENTA ENANTA PHARMACEUTICALS INC 29 Apr 2024 0 $0 3 Chief Legal Officer 01 May 2024, 16:25
/report/000141588923012133-kowalsky-matthew-paul-2023-08-11 Sigilon Therapeutics, Inc. 11 Aug 2023 2 -$9,518 4 CHIEF OF STAFF AND CLO 11 Aug 2023, 16:10
/report/000141588923003686-kowalsky-matthew-paul-2023-02-28 Sigilon Therapeutics, Inc. 28 Feb 2023 1 $0 4 CHIEF OF STAFF AND CLO 01 Mar 2023, 15:46
/report/000141588923003671-kowalsky-matthew-paul-2023-02-28 Sigilon Therapeutics, Inc. 28 Feb 2023 0 $0 3 CHIEF OF STAFF AND CLO 01 Mar 2023, 15:35